Opinion channel feed

Opin­ion: How the con­fus­ing boost­er shot de­ba­cle aligns Biden with Trump's pan­dem­ic re­sponse

4 years ago
Coronavirus

Opin­ion: Pric­ing in­fo with new drug ap­provals: Time for trans­paren­cy

4 years ago
FDA+

Opin­ion: The FDA's mR­NA vac­cine full ap­proval re­views are mov­ing plen­ty fast. Start the man­dates now

4 years ago
FDA+

Opin­ion: CMS needs to do FDA’s job and lim­it the use of Bio­gen’s pricey new Alzheimer’s drug

4 years ago
FDA+

Opin­ion: How the FDA bent its rules for Bio­gen’s Alzheimer’s drug and why that’s bad for the en­tire bio­phar­ma in­dus­try

4 years ago
FDA+

Opin­ion: It shouldn’t mat­ter who the FDA com­mis­sion­er is when it comes to con­tro­ver­sial drug ap­proval de­ci­sions

4 years ago
FDA+

Opin­ion: Con­gress needs to take a hard look at what went on at Trump's White House dur­ing the pan­dem­ic

4 years ago
FDA+

Opin­ion: Ado­les­cents can wait. The US needs to start do­nat­ing Covid-19 vac­cines to needy coun­tries now.

5 years ago
FDA+

Opin­ion: Waiv­ing Covid-19 vac­cine IP could save lives, but where is the man­u­fac­tur­ing ca­pac­i­ty?

5 years ago
FDA+

Opin­ion: Mean­ing­ful drug pric­ing re­forms are head­ed nowhere fast

5 years ago
Pharma
FDA+

Opin­ion: US and EU re­views of blood clots and J&J’s Covid vac­cine show why a trans­par­ent process mat­ters

5 years ago
FDA+

Re­cur­sion founders gin for­tunes as IPO back­ers show­er $436M on one of the biggest boasts in AI — based on some very small deals

5 years ago
Bioregnum

Opin­ion: Pfiz­er, BioN­Tech did­n't take US gov­ern­men­t's sup­port to de­vel­op their vac­cine. Let's stop rewrit­ing the facts

5 years ago

Ac­tivist in­vestor grabs a multi­bil­lion-pound stake in Glax­o­SmithK­line, trig­ger­ing buzz about a loom­ing show­down at the list­less gi­ant

5 years ago
Bioregnum
R&D

Opin­ion: Biden needs to step up and nom­i­nate an FDA com­mis­sion­er

5 years ago
FDA+

Can he pick them? A high-pro­file Wall Street an­a­lyst jumps in­to biotech as CFO of an on­col­o­gy up­start

5 years ago
People
Bioregnum

Roger Perl­mut­ter’s lat­est ‘re­tire­ment’ gig opens a door to the bustling Chi­na biotech scene

5 years ago
Bioregnum
China

A de­part­ing CMO pens a sad farewell as he heads back to the UK bio­phar­ma scene

5 years ago
People
Bioregnum

Eli Lil­ly touts a 'con­stel­la­tion' of suc­cess­es with their PhII Alzheimer’s study — but dis­ap­point­ing fail­ures drag down shares

5 years ago
Bioregnum
R&D

Jeff Hat­field as­sem­bles a syn­di­cate with some A-list pub­lic in­vestors in the mix as Vi­vid­ion adds $135M raise

5 years ago
Financing
Bioregnum

The $1M IPO bonus, de­cent pay and a nice eq­ui­ty stake to mark the up­side: How does Mark McKen­na's comp pack­age stack up in the Nas­daq rush?

5 years ago
Financing
Bioregnum

Bio­phar­ma ex­ecs rou­tine­ly shun re­veal­ing the hard truth when it comes to RTFs. And some peo­ple at the FDA think that's a big prob­lem

5 years ago
Bioregnum
FDA+

One of the gi­ant vac­cine play­ers push­es back against a ‘fun­da­men­tal shift’ spurred by mR­NA. But is the CEO just whistling past the grave­yard?

5 years ago
Bioregnum
Coronavirus

Is it time to stock up on wine? This pan­dem­ic could stretch out — and that has some ma­jor mar­ket im­pli­ca­tions

5 years ago
Bioregnum
1234 Next page Last page
A service from the Financial Times
OSZAR »